Macrogenics Inc * Macrogenics presents information from phase 1 research of mgd010 at
yearly european congress of rheumatology (eular 2016).
* Mgd010 was well endured at all dosage levels with no.
severe unfavorable results.
* Bispecific particle based on dart platform at the same time.
targets b-cell antigens, CD32B and CD79B.
Source text for Eikon:.
Further business protection:.